Similarly, Xia et al. (2024) created another ~72.5 nm nanomicelles from a HER2-Affibody-epothilone B conjugate, exhibiting slower blood clearance (~5.6 μg/mL at 12 h) than free affibody (~0.4 μg/mL), greater tumor retention, and exceptional tumor inhibition at 10 mg/kg [43]. Here, ERBB2 is linked to neoplasm.